Benign prostatic hyperplasia (BPH) is an androgen-dependent disease; it originates exclusively in the inner prostate, which includes tissue surrounding the urethra. Stromal-epithelial interaction has a pivotal role in the regulation of the development and growth of the prostate, and locally produced peptide growth factors are considered important mediators of this interaction. Insulin-like growth factor I (IGF-I) and IGF-II, acting mainly through type 1 IGF receptor (IGFR1), have mitogenic and antiapoptotic effects on epithelial and stromal prostatic cells. In this study the expression of IGF-I, IGF-II, and IGFR1 messenger ribonucleic acid (mRNA), the immunoreactive content of IGF-I (irIGF-I) and IGF-II (irIGF-II) were determined in periurethral, intermediate, and subcapsular regions of BPH tissue to verify their possible regional variation; a correlation to the tissue levels of dihydrotestosterone (DHT) and 3␣-androstanediol (3␣Diol) was also determined to verify their possible androgen dependence.
DHT and 3␣Diol concentrations were evaluated by RIA after extraction and purification on Celite microcolumns.
IGF-II and IGFR1, but not IGF-I, mRNA was higher in the periurethral than in the intermediate (P Ͻ 0.05) and subcapsular (P Ͻ 0.01) region. Also, prostatic levels of irIGF-II, expressed as picomoles per g tissue, were higher in the periurethral (20.84 Ϯ 1.84) than in the intermediate (14. 81 Ϯ 2.11; P Ͻ 0.05) and subcapsular (10.88 Ϯ 1.21; P Ͻ 0.001) region. No significant differences were found in irIGF-I content. Considering prostatic androgen levels, DHT and 3␣Diol presented a regional variation, with the highest concentrations in the periurethral region. IGF-II mRNA and irIGF-II levels were positively correlated with both DHT and 3␣Diol content.
These results demonstrate that in BPH tissue a greater IGF-II activity is present in the periurethral region, the site of origin of BPH. Moreover, we can hypothesize that the tissue androgen content may modulate prostatic production of IGF-II, acting at the transcriptional and probably the posttranscriptional level. Therefore, even though further studies will need to confirm this hypothesis, DHT may increase IGF-II activity, mainly in the periurethral region, which, in turn, induces, through IGFR1, benign proliferation of both epithelial and stromal cells, characteristic of BPH. (J Clin Endocrinol Metab 86: 1700 -1706, 2001) I N NORMAL HUMAN prostate two parts can be distinguished: the inner and the outer (1) . The first one includes the transitional and periurethral zones and surrounds the proximal segment of the urethra, extending from the verumontanum to the bladder neck. The outer prostate includes the peripheral and central zones and represents the most part of the gland. This anatomical distinction is of particular clinical interest because benign prostatic hyperplasia (BPH) originates only in the inner prostate, whereas prostatic cancer arises almost exclusively in the outer prostate.
The stromal-epithelial interaction plays a critical role in the regulation of the differentiation, growth, and function of the prostate gland (2) (3) (4) . In particular, experiments using epithelium/stroma cocultures have shown that 1) the stroma is the inductor of prostatic development during both embryogenesis and puberty; and 2) adult prostatic epithelium, normally quiescent in adulthood, remains responsive to the products arising from the embryonic urogenital sinus stroma cells, which are responsible for growth and changes in morphology and differentiation of the epithelial cells. These findings suggest that stroma-epithelial interaction is important not only during embryogenesis and puberty, but also in adulthood and therefore may be implicated in the pathogenesis of proliferative prostatic diseases. In particular, McNeal (5) suggested that BPH may be caused by reactivation of the inductive activity of the stroma in adulthood, which is responsible for benign proliferation of both stroma and epithelium through autocrine and paracrine effects. For the development of the normal prostate and its proliferative diseases, adequate androgen stimulation is required, and it is essential (6) . At least during prostatic de-velopment, the stroma is the mediator of part of the androgenic actions on the epithelium (2). However androgen stimulation alone does not completely explain the development of BPH, probably because androgen action is only in part direct and is mainly indirect through prostatic production of some growth factors (7) . These locally produced peptides are considered to be autocrine and/or paracrine mediators of the stromal-epithelial interaction, and abnormal synthesis and secretion of these peptides may be related to the inductive embryonic capacities of the stroma (8) .
Insulin-like growth factor I (IGF-I) and IGF-II are two important growth factors (9) . They interact with two specific membrane receptors: the type 1 (IGFR1) and the type 2 (IGFR2) IGF receptors (10) . However most of the biological actions of IGFs, in particular mitogenic and antiapoptotic effects, are mediated via the IGFR1 (11), which is composed of two ␣-subunits, with ligand-binding sites, and two ␤-subunits, with intrinsic tyrosinic activity (10) . In the prostate the most important source of IGF production is the stroma (12) (13) (14) . However, IGFR1 has been identified mainly in the epithelial compartment, but it is also present in the stroma (15) (16) (17) .
In vitro studies, using primary cultures of epithelial and stromal cells, have shown a different protein distribution of IGFs and their binding proteins in the different regions of the prostate (14) . However, as far as we know, no in vivo studies have been performed on IGF production and its possible androgen dependence in the different regions of the human prostate. To clarify this aspect we determined the expression of IGF-I, IGF-II, and IGFR1 messenger ribonucleic acid (mRNA); the immunoreactive levels of IGF-I (irIGF-I) and IGF-II (irIGF-II); and dihydrotestosterone (DHT) and 3␣-androstanediol (3␣Diol) contents in periurethral, intermediate, and subcapsular regions of BPH tissue.
Subjects and Methods Patients
The population studied included 14 patients with established BPH (age range, 57-79 yr; mean age, 67.21 Ϯ 6.88 yr). The 14 men had no history of outlet surgery, prostatitis, neurogenic disorders, urinary bacterial infections, or other conditions known to interfere with normal voiding bladder, except BPH. There was no evidence of prostate cancer on digital rectal examination or transrectal ultrasonography. In all cases the clinical diagnosis of BPH was confirmed by histological examination. None of the patients had received any prior treatment. The study was approved by our local ethical committee, and all patients gave written informed consent.
Prostatic tissue
BPH tissues were removed by suprapubic prostatectomy. As previously described, from each enucleated benign hyperplastic prostate gland three different regions were obtained: the periurethral, intermediate, and subcapsular zones (18, 19) . Each prostate was sectioned on a frontal plane parallel to the urethra, in front of and behind it; the remaining tissue, represented by the two lateral portions of the gland, was cut along the sagittal plane, parallel to the urethra, into sections of 0.6 cm; the most internal was the periurethral region, the outer one was the subcapsular, and the one included between these two was the intermediate region. Each region weighed about 1 g. Immediately, prostatic samples were put in liquid nitrogen and processed or stored at Ϫ80 C for no more than 1 month.
Tissue specimens were analyzed in three ways. The first was a histological examination to confirm the diagnosis of BPH; to exclude carcinoma, inflammation, and other possible confounding variables; and to evaluate morphometric characteristics of the different prostatic regions by stereological analysis. The second was RT-PCR analysis to evaluate gene expression of IGF-I, IGF-II, and IGFR1. In the third, tissue samples were pulverized in liquid nitrogen with a porcelain mortar and then homogenized in 5 vol TEGM buffer (0.01 mol/L Tris-HCl, 0.001 mol/L ethylenediamine tetraacetate, 0.002 mol/L mercaptoethanol, 0.02 mol/L sodium molybdate, 0.001 mol/L phenylmethylsulfonylfluoride, 0.001 mol/L dithiothreitol, and 10% glycerol, pH 7.4, at 25 C) (20) to determine irIGF-I, irIGF-II, DHT, and 3␣Diol by RIA or immunoradiometric assay (IRMA).
Histological analysis
Prostatic samples were cut in 4-m-thick sections and stained with hematoxylin and eosin. After histological diagnosis of BPH, prostatic tissues were morphometrically evaluated using a stereological analysis (21) to determine whether the histological compositions of the different prostatic regions influence our results.
RNA extraction and RT-PCR
Total RNA was extracted from prostatic tissues by the acid guanidinium thiocyanate-phenol-chloroform method (22) . After precipitation, RNA pellets were dissolved in diethylpyrocarbonate-treated water and quantified spectrophotometrically at 260 nm; the integrity of the extracted RNA was verified by agarose gel electrophoresis. Typically, single stranded complementary DNA (cDNA) was synthesized from total RNA by RT, using Moloney murine leukemia virus reverse transcriptase (Promega Corp., . Primers used for human IGF-II and IGFR1 have been described previously (23) , whereas primers used for human IGF-I were designed by us; each primer pair was localized on different exons to evaluate the presence of contaminating genomic DNA. The sequences of oligonucleotide primers are reported in Table 1 . These primers amplify IGF-I, IGF-II, and IGFR1 sequences of 270, 153, and 300 bp, respectively. The PCR reactions were carried out on a DNA thermocycler and consisted of denaturation at 94 C for 30 s, annealing at 65 C for 30 s, and extension at 72 C for 60 s. The denaturation phase of the first cycle was prolonged by 5 min, and the extension phase of the last cycle was prolonged by 9 min. The number of cycles was determined previously to be within the exponential range of PCR product amplification necessary for quantitative densitometry and was 27 for IGF-II, 30 for IGFR1, and 32 for IGF-I. A specific unpublished primer pair ( Table   TABLE 1 
1) was used for the amplification of human ␤-actin, a housekeeping gene used to control PCR reactions and to normalize mRNA levels of IGF-I, IGF-II, and IGFR1. PCR amplification of ␤-actin was carried out using the protocol described above for 25 cycles. Negative controls included the substitution of cDNA templates with an equal volume of distilled water and were amplified in parallel to check contamination of the samples. To evaluate the presence of the contaminating genomic DNA in the RNA-extracted preparation, a PCR reaction, where the cDNA was replaced with a corresponding quantity of total RNA extracted, was performed without obtaining amplification. At least two independent RTs, starting from two different RNA extractions, and at least six separate PCRs (three for each RT) were performed for each sample. The PCR-amplified products were analyzed by electrophoresis on a 2% agarose gel in TAE running buffer (40 mmol/L Tris base, 20 mmol/L sodium acetate, and 0.5 mmol/L ethylenediamine tetraacetate) and visualized by ethidium bromide staining under UV light. The intensities of the bands were quantified by densitometric analysis and normalized to that of the ␤-actin.
IGF assays
irIGF-I and irIGF-II were measured in tissue homogenate, as previously described (24) . The extraction and purification procedures consisted of acidification and filtration on Sep-Pak C 18 cartridges (Waters Corp., Milford, MA) (25) to eliminate IGF-binding protein (IGFBP), which interferes with IGF radioligand assays (26) . After centrifugation of the homogenate at 800 ϫ g for 10 min, the resulting supernatant was acidified with HCl to a final 0.5-n concentration, stirred at room temperature for 45 min, and centrifuged at 1400 ϫ g for 20 min. A second extraction of the pellet, under the same conditions, was performed, and the supernatants of the two extractions were loaded onto a prewashed Sep-Pak C 18 cartridge. The IGFBPs were eliminated by washing with 10 mL 4% acetic acid, and the IGFs were eluted with 5 mL 95% acetonitrile-5% H 2 O containing 0.1% trifluoroacetic acid. The filtration was repeated for a second time under the same conditions, and the eluate was dried on a Speed-Vac rotor and neutralized with assay buffer. Prostatic irIGF-I and irIGF-II were determined in triplicate at two different dilutions by RIA (Medgenix Diagnostic, Fleurus, Belgium) and IRMA (Diagnostics Systems Laboratories, Inc., Webster, TX), respectively, using commercial kits. The sensitivity of the IGF-I assay was 25 pg/tube, and the inter-and intraassay coefficients of variation were 8.2% and 4.1%, respectively. The sensitivity of the IGF-II assay was 13 pg/tube, and the inter-and intraassay coefficients of variation were 7.9% and 4.2%, respectively.
The mean recoveries of [ 125 I]IGF-I (NEN Life Science Products, DuPont, Boston, MA) and [
125 I]IGF-II (Diagnostics Systems Laboratories, Inc.), incubated for 24 h at 4 C at the beginning of the extraction procedure to monitor the recovery of endogenous IGFs, were 84 Ϯ 5% and 88 Ϯ 4%, respectively. The recoveries of three different concentrations of unlabeled human IGF-I (3, 9, and 15 ng/mL) and IGF-II (15, 45, and 75 ng/mL) incubated for 24 h at 4 C with two different homogenates were 84%, 90%, and 92% and 87%, 89%, and 91%, respectively, for IGF-I, and 88%, 90%, and 93% and 89%, 90%, and 94%, respectively, for IGF-II.
To evaluate whether binding proteins that may produce artifacts in IGFs assays have been removed, we evaluated in the extracted samples IGF-I and IGF-II concentrations in the presence of an excess of IGF peptide, specifically by adding 100 ng/mL IGF-II in the IGF-I assay and 400 ng/mL IGF-I in the IGF-II assay, saturating the possible residual IGFBPs (27) . Comparing the concentrations of IGF-I and IGF-II obtained with and without excess IGFs, we found similar results. Moreover, a second procedure to evaluate whether IGFBPs had been completely removed was performed: an aliquot of the extracted specimens for the assay of IGFs was used to evaluate the presence of IGFBP-1 by IRMA and of IGFBP-2, IGFBP-3, and IGFBP-6 by RIA, using commercial kits (Diagnostics Systems Laboratories, Inc.) (25) . No detectable IGFBP was found in any sample. Both of these procedures confirm the validity of our IGFs extraction and purification methods.
Androgen assay
DHT and 3␣Diol were determined in the homogenate tissue, as previously described (28) . [ 3 H]DHT and [ 3 H]3␣Diol (NEN Life Science Products, DuPont; 2000 cpm each) were added to each homogenate to monitor the recovery of endogenous androgens (DHT and 3␣Diol) after extraction and purification methods. The homogenate was extracted with 5 vol ice-cold acetone, stirred at 4 C for 60 min, and centrifuged at 1400 ϫ g for 20 min. The supernatant was collected, and the pellet was extracted a second time as described above. The two resulting supernatants were united, dried under nitrogen, extracted twice with 5 vol ether, and redried under nitrogen. The sample was resuspended in isooctane and loaded on Celite microcolumns. DHT and 3␣Diol were eluted with a mixture of isooctane-benzene (60:40, vol/vol, and 40:60, vol/vol, respectively) (29) . The eluates were dried under nitrogen and resuspended in phosphate buffer. Intraprostatic levels of DHT and 3␣Diol were determined by RIA in duplicate at two different dilutions using a commercial kit (Diagnostics Systems Laboratories, Inc.) and specific antibody from Sera-Lab Ltd. (Crawley Down, UK), respectively, as previously described (28) 
Statistical analysis
Correlation of degrees of association for any two parameters was determined by Pearson's r correlation test and validated by Spearman's rank and Kendal correlation tests. Regional variations in irIGF-I, irIGF-II, IGF-I mRNA, IGF-II mRNA, IGFR1 mRNA, DHT, and 3␣Diol were determined by paired t test. P Ͻ 0.05 was considered significant.
Results

IGF-I, IGF-II, and IGFR1 mRNA expression
RT-PCR analysis was performed using specific primers for human IGF-I, IGF-II, and IGFR1; the PCR products were of the expected sizes of 270, 153, and 300 bp, respectively (Fig. 1) . In all samples examined, expression of these three genes was found. No amplification was observed when cDNA was replaced with distilled water (negative control) or total RNA; the latter excludes contamination of genomic DNA, also demonstrated by the absence of amplification of fragments longer than those expected. Using the housekeeping gene ␤-actin as a control, periurethral, intermediate, and subcapsular zones had similar levels of IGF-I mRNA ( Fig. 2A) . In contrast, a higher expression of IGF-II and IGFR1 mRNA was found in the periurethral zone than in the intermediate (P Ͻ 0.05) and subcapsular (P Ͻ 0.01) regions (Fig. 2, B and C) .
Immunoreactive IGF-I and IGF-II
irIGF values are reported as the mean Ϯ se and expressed as picomoles per g tissue. irIGF-I levels were 3.92 Ϯ 0.69 in the periurethral, 3.69 Ϯ 0.78 in the intermediate, and 3.11 Ϯ 0.37 in the subcapsular region, but no significant differences were found in the three zones (Fig. 3A) . In contrast, in the periurethral region irIGF-II concentrations (20.84 Ϯ 1.84) were higher than those in the intermediate (14.81 Ϯ 2.11; P Ͻ 0.05) and subcapsular (10.88 Ϯ 1.21; P Ͻ 0.001) regions (Fig. 3B) . In the three prostatic zones, levels of irIGF-II were always higher than those of irIGF-I (P Ͻ 0.0001).
DHT and 3␣Diol levels
Tissue androgen levels are reported as the mean Ϯ se and expressed as picomoles per g tissue. Prostatic DHT levels were significantly higher in the periurethral (25.82 Ϯ 1.68) than in the intermediate (16.21 Ϯ 1.44; P Ͻ 0.001) and subcapsular (14.08 Ϯ 1.75; P Ͻ 0.001) regions (Fig. 4A) . Similarly, tissue 3␣Diol concentrations were significantly higher in the periurethral than in the intermediate (P Ͻ 0.01) and subcapsular (P Ͻ 0.001) regions, with values of 6.18 Ϯ 0.61, 3.72 Ϯ 0.61, and 2.76 Ϯ 0.51, respectively (Fig. 4B) .
Morphometric analysis
A morphometric study was performed to evaluate the percentage of stroma, epithelium, and glandular lumen in each region of the prostate, which may influence our data. In fact, it is known that prostatic stroma is the most important source of IGF production (12) (13) (14) and is particularly rich in 5␣-reductase, the enzyme responsible for DHT production (30, 31) . The periurethral region contained a mean (Ϯsd) of 67 Ϯ 10.9%, 14.1 Ϯ 7.2%, and 18 Ϯ 5.9% stroma, epithelium, and glandular lumen, respectively. The No statistically significant differences were found between stroma, epithelium, and glandular lumen content and stroma/epithelium ratio in the three zones analyzed. The regional variations in IGF-II and IGFR1 mRNA, irIGF-II, DHT, and 3␣Diol, but not in IGF-I mRNA and protein, were also observed when the content of each region was compared with the correspondent histological composition (stroma, epithelium, and glandular lumen content and stroma/epithelium ratio), excluding an influence of tissue morphometric characteristics in our result.
Correlation analysis
Correlation of degrees of association between two parameters was evaluated both separately in each region and considering the three regions as a whole. Positive linear correlations between the levels of DHT and IGF-II mRNA, DHT and irIGF-II, DHT and IGFR1 mRNA, 3␣Diol and IGF-II mRNA, 3␣Diol and irIGF-II, and 3␣Diol and IGFR1 mRNA were seen in all of the conditions studied (Table 2) ; moreover, a linear positive correlation between the levels of DHT and irIGF-I and between 3␣Diol and irIGF-I was found only in the periurethral region.
No correlation was demonstrated between histological characterizations (stroma, epithelium, and glandular lumen content and stroma/epithelium ratio) of prostatic tissue and IGF-I, IGF-II, and IGFR1 mRNA; irIGF-I; irIGF-II; DHT; and 3␣Diol.
Discussion
In this study we evaluated both gene expression and protein content of IGF-I and IGF-II in periurethral, intermediate, and subcapsular regions of BPH tissue. All regions present measurable levels of both mRNA and protein of IGF-I and IGF-II, demonstrating that BPH tissue synthesizes and secretes these peptides. This observation is important mainly for IGF-I. In fact, previous in vitro studies using primary cultures from normal and BPH tissues have shown that epithelial and stromal prostatic cells are unable to produce IGF-I (13, 14, 17) . In contrast, previous in vivo studies using BPH tissue have demonstrated the presence of IGF-I mRNA and protein in prostatic samples (23, 32, 33) . The differences between in vitro and in vivo studies may be related to the fact that in in vitro studies the epithelial and stromal prostatic cells grow separately, with a possible altered production and secretion of factors involved in the stromal-epithelial interaction, such as IGFs.
In our study no significant differences in mRNA and protein levels of IGF-I are present in the three regions of BPH tissue, even though in the periurethral region irIGF-I is 20% higher than in the subcapsular region. Therefore, these data do no definitively rule out a role of IGF-I in BPH, because it is possible that with a larger number of prostatic samples this difference could be significant.
IGF-II mRNA and irIGF-II levels present a significant regional variation, with higher values in the periurethral zone, where the disease originates, than in the subcapsular and intermediate regions. These results are in agreement with those of Boudon et al. (14) obtained in vitro using primary cultures of epithelial and stromal prostatic cells grown separately; they have, in fact, demonstrated that IGF-II protein concentrations secreted in stroma cell culture medium from normal prostate were higher in the periurethral zone than in the peripheral zone.
Considering that IGFBPs are important modulators of IGF action, regulating IGFs availability for their receptor (10), it is possible that variations in IGFBP prostatic secretion may occur in BPH tissue, neutralizing the highest concentrations of IGF-II of the periurethral region. However, even though we have no data regarding IGFBPs, our findings suggest that the different levels of IGF-II found in the three regions are associated with different IGF actions. Specifically, the highest TABLE 2. Correlation of degrees of association between two parameters was evaluated both separately in each region and considering the three regions as a whole levels of IGF-II mRNA and irIGF-II in the periurethral region appear related with an increase in free IGF-II available for IGFR1 interaction, as a corresponding modification of IGFR1 mRNA content is present in this region. Therefore, because antiapoptotic and mitogenic effects of IGF-II are mediated by IGFR1 (11) and because in prostatic tissue it has been reported that high mRNA levels of IGFR1 are associated with high protein content of IGFR1 (15), our results, showing the highest levels of IGF-II mRNA, irIGF-II, and IGFR1 mRNA in the periurethral region of BPH, strongly support the possibility that in this region a greater IGF-II activity is present.
During the fetal period, IGF-II is expressed at high levels in the rapidly growing tissues (34) , and in primary cultures of stromal cells the content of IGF-II mRNA is 10-fold higher in those derived from BPH than in those from normal prostate (35) . These findings support the hypothesis that BPH represents a return of the prostatic adult stroma to a fetal status (5), with IGF-II considered a mediator of the reawakening of the embryonic capacities of the prostatic stroma. In particular, a greater action of IGF-II in the periurethral region, where the primitive micronodular lesion of the disease originates, may cause BPH growth acting on both epithelial and stromal cells through paracrine and autocrine effects.
In our previous study performed on whole BPH tissue, a linear positive correlation between irIGF-II and both DHT and 3␣Diol levels was observed (24) . In this study, where the three regions are considered, both IGF-II mRNA and irIGF-II were positively correlated with DHT, suggesting that this hormone may be a modulator of the prostatic synthesis and secretion of IGF-II, acting at the transcriptional and probably the posttranscriptional level. Alternatively, the correlation between both IGF-II mRNA and irIGF-II and DHT may be a casual event or may be due to the fact that DHT formation in BPH tissue is IGF-II dependent. This latter hypothesis is suggested by the observation that 5␣-reductase activity of human scrotal skin fibroblasts is increased by IGF-I stimulation through IGFR-1 activation, but this effect is not reproduced by IGF-II (36) . Therefore, even though the positive correlation between both IGF-II mRNA and irIGF-II and DHT does not necessarily prove causality, it suggests that DHT may regulate prostatic IGF-II production, and then the regional variation of this growth factor may better reflect its androgen dependence. According to this hypothesis it has been recently demonstrated that androgen deprivation reduces IGF-II mRNA levels in prostatic cells (37) .
Both IGF-II mRNA and irIGF-II were also correlated with 3␣Diol. These data may reflect the origin of this metabolite. In fact, 70% of 3␣Diol derives from the reduction of DHT (38) , as confirmed by the positive linear correlation between these two androgens observed in this study. In particular, it may be possible that intraprostatic 3␣Diol originates mostly from DHT bound to nuclear androgen receptor and then is active at the genomic level (28) . From this point of view, 3␣Diol may be a valuable marker of prostatic androgenization (28) . However, it cannot be excluded that 3␣Diol is involved in the control of prostatic synthesis and secretion of IGF-II, acting either indirectly, through back-conversion to DHT, or directly, through activation of the sex hormone-binding globulin/sex hormonebinding globulin receptor complex (39, 40) .
Unlike IGF-II, whose gene and protein expression appears to be dependent on androgen stimulation of BPH tissue, the intraprostatic content of IGF-I may be modulated by androgens only in the periurethral region and exclusively at the posttranscriptional level. In fact, in the periurethral region only irIGF-I, but not IGF-I mRNA, was correlated with both DHT and 3␣Diol, whereas in the intermediate and subcapsular regions no correlation was present between IGF-I mRNA and irIGF-I and both DHT and 3␣Diol.
Our results, then, suggest that in BPH tissue, androgens control IGF-II and only in part IGF-I production. These data are only apparently in disagreement with the recent report showing that the DHT deprivation during finasteride treatment induces a reduction of IGF-I protein content in BPH tissue evaluated by immunostaining (41) . This study, in fact, was performed exclusively on the first chips of the periurethral prostatic tissue obtained by transurethral prostatectomy. The samples studied, therefore, approximately correspond to the periurethral region of our study obtained by suprapubic prostatectomy.
It is known that in the prostate the stroma is the major source of IGFs (12) (13) (14) and is particularly rich in 5␣-reductase (30, 31) , the enzyme responsible for DHT formation. Therefore, we performed morphometric analysis of the periurethral, intermediate, and subcapsular regions, excluding that histological composition may be responsible for the differences observed. In fact, IGF-II and IGFR1 mRNA, irIGF-II, DHT, and 3␣Diol were significantly higher in the periurethral zone than in the intermediate and subcapsular regions and when their content was normalized to the stroma, epithelium, and glandular lumen content and the stroma/epithelium ratio.
The different androgen dependence of IGF-I and IGF-II may be responsible for the different distributions of the two growth factors in BPH tissue. In fact, we can hypothesize that IGF-II presents a significant regional variation, with highest levels in the periurethral region, as its synthesis and secretion correlated to the androgen content in all three regions of BPH analyzed. However, further studies will need to be performed to confirm this hypothesis.
This study confirms our previous investigations (18, 28) , showing a relative hyperandrogenism of the periurethral zone, with the highest levels of DHT, 3␣Diol, and nuclear androgen receptor compared to the subcapsular and intermediate regions. This assumption is supported by the preferential size reduction of the periurethral region during DHT deprivation (42) .
The most acceptable hypothesis to explain the androgen distribution, having excluded that histological composition may be responsible for the periurethral accumulation of DHT (18) , is the transfer of testosterone/DHT from the vas deferens and/or the deferential veins, where these androgens are present at high concentrations, to the prostatic tissue (20, 43, 44) . In fact, the vas deferens reachs the urethra passing through the prostate, and the transfer of material from the deferential vein to the prostate has been demonstrated in the dog (45) , which has an anatomical situation similar to that in man. This hypothesis may explain the fact that man and dog are the only two species affected by BPH.
In conclusion, the results of this study demonstrate that in BPH tissue 1) a regional variation in IGF-II, but not IGF-I, is present, where gene and protein expressions of IGF-II are higher in the periurethral region than in the intermediate and subcapsular regions; 2) the highest levels of IGF-II mRNA and irIGF-II are associated with the highest levels of IGFR1 mRNA, the receptor that mediates IGF-II effects, indicating a greater action of IGF-II in the periurethral region; 3) IGF-II synthesis and secretion may be androgen-dependent events, as both IGF-II mRNA and irIGF-II are correlated with tissue DHT and 3␣Diol levels, which are higher in the periurethral than in the intermediate and subcapsular regions. Because a simple correlation does not prove causality, further studies are needed to confirm this hypothesis. However, on the basis of our data, it is possible that in BPH tissue DHT may increase gene and protein expression of IGF-II, mainly in the periurethral region where the disease originates. IGF-II, which may be the mediator of reawakening of the embryonic capacities of the adult prostatic stroma, induces, through IGFR1, a benign proliferation of both epithelial and stromal cells, which is characteristic of BPH, particularly in the periurethral region whose enlargement is responsible for urinary obstruction.
